• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cardiovasc Revasc Med . Implications of left ventricular function on short-term outcomes in COVID-19 patients with myocardial injury

tetano

Editor, Senior Moderator
Cardiovasc Revasc Med


. 2021 Apr 6;S1553-8389(21)00188-3.
doi: 10.1016/j.carrev.2021.03.028. Online ahead of print.
Implications of left ventricular function on short-term outcomes in COVID-19 patients with myocardial injury


Giorgio A Medranda[SUP] 1 [/SUP], Hooman Fazlalizadeh[SUP] 2 [/SUP], Brian C Case[SUP] 3 [/SUP], Charan Yerasi[SUP] 4 [/SUP], Cheng Zhang[SUP] 5 [/SUP], Hank Rappaport[SUP] 6 [/SUP], Corey Shea[SUP] 7 [/SUP], William S Weintraub[SUP] 8 [/SUP], Ron Waksman[SUP] 9 [/SUP]



Affiliations

Abstract

Background: Myocardial injury is a complication of coronavirus disease 2019 (COVID-19). We describe a large multi-center experience of COVID-19 patients with myocardial injury, examining the prognostic role left ventricular function plays on short-term outcomes.
Methods/materials: We included adult COVID-19 patients admitted to our health system with evidence of myocardial injury and who underwent a transthoracic echocardiogram (TTE) during index admission. Patients were dichotomized into those with reduced ejection fraction (EF; <50%) and preserved EF (≥50%).
Results: Across our 11-hospital system, 5032 adult patients were admitted with COVID-19 from March-September 2020. Of these, 235 had evidence of myocardial injury (troponin ≥1 ng/mL). Included were 134 patients who underwent TTE, of whom 43.3% (n = 58) had reduced EF and 56.7% (n = 76) preserved EF. A subset of 6 patients had newly reduced EF, with 5 demonstrating evidence of stress cardiomyopathy and subsequently dying. Overall, mortality was high in those with reduced EF and preserved EF (in-hospital: 34.5% vs. 28.9%; p = 0.494; 6 months: 63.6% vs. 50.0%; p = 0.167; Kaplan-Meier estimates: p = 0.2886). Readmissions were frequent in both groups (30 days: 22.2% vs. 26.0%; p = 0.162; 6 months: 52.0% vs. 54.5%; p = 0.839).
Conclusions: Many COVID-19 patients admitted with evidence of myocardial injury did not undergo TTE. For those who did, short-term mortality was high. Patients who survived hospitalization had frequent readmissions. In patients with newly reduced EF, most had evidence of stress cardiomyopathy and expired. Larger studies are needed to fully evaluate the prognosis of COVID-19 patients with evidence of myocardial injury and left ventricular dysfunction.

Keywords: COVID-19; Left ventricular ejection fraction; Myocardial injury; Readmission; Troponin.
 
Back
Top Bottom